Skip to main content
. 2019 Jun 19;20(1):73–80. doi: 10.1007/s40256-019-00353-5

Fig. 1.

Fig. 1

Cumulative hazard ratio (%) of a new-onset atrial fibrillation (AF) and b recurrence of AF for spironolactone versus placebo